Loading…

A Proposed Methodology for a Risk Assessment-Based Liposome Development Process

The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and pr...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2020-11, Vol.12 (12), p.1164
Main Authors: Németh, Zsófia, Pallagi, Edina, Dobó, Dorina Gabriella, Csóka, Ildikó
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3
cites cdi_FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3
container_end_page
container_issue 12
container_start_page 1164
container_title Pharmaceutics
container_volume 12
creator Németh, Zsófia
Pallagi, Edina
Dobó, Dorina Gabriella
Csóka, Ildikó
description The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and process parameters (PPs) (settings of the preparation method). The identification of the quality target product profile for a liposome-based formulation, the critical quality attributes of the liposomes, and the possible MAs and PPs that may influence the key characteristics of the vesicles facilitates pharmaceutical research. Researchers can systematise their knowledge by using the quality by design (QbD) approach. The potential factors that influence the quality of the product can be collected and studied through a risk assessment process. In this paper, the requirements of a liposome formulation prepared via the thin-film hydration preparation technique are presented; furthermore, the possible factors that have an impact on the quality of the final product and have to be considered and specified during the development of a liposomal formulation are herein identified and collected. The understanding and the application of these elements of QbD in the pharmaceutical developments help to influence the quality, the achievements, and the success of the formulated product.
doi_str_mv 10.3390/pharmaceutics12121164
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7f1d87539f2646de9cb0f6e7f79ca7e7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7f1d87539f2646de9cb0f6e7f79ca7e7</doaj_id><sourcerecordid>2467238502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3</originalsourceid><addsrcrecordid>eNptkk1P3DAQhi3UqiDKTyiK1Esvaf3t-FJp-WqRFoFQe7YcZ7ybbbJO7QSJf4_DUgSo9sEjzzOv_I4HoU8Ef2VM42_D2sbeOpjG1iVC8yaS76EDorUuuabs3Yt4Hx2ltMF5MUYqpj-gfcaoxJyzA3S9KG5iGEKCpriCcR2a0IXVfeFDLGxx26Y_xSIlSKmH7Vie2JlbtpkPPRRncAddGObUrOIy9hG997ZLcPR0HqLfF-e_Tn-Wy-sfl6eLZekEFmMpGLOEaC69rLgSjaot195VUtcgndOEskroJhvztXAgFYbsklLJMHeicuwQXe50m2A3Zohtb-O9CbY1jxchroyNuTsdGOVJUynBtKeSywa0q7GXoLzSzipQWev7TmuY6h4al-1E270SfZ3ZtmuzCndGKYkrxbPAlyeBGP5OkEbTt8lB19kthCkZyqWkmjM6o5_foJswxW1u1Uyp2TammRI7ysWQUgT__BiCzTwB5r8TkOuOXzp5rvr33-wBJlmvrg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2467238502</pqid></control><display><type>article</type><title>A Proposed Methodology for a Risk Assessment-Based Liposome Development Process</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Németh, Zsófia ; Pallagi, Edina ; Dobó, Dorina Gabriella ; Csóka, Ildikó</creator><creatorcontrib>Németh, Zsófia ; Pallagi, Edina ; Dobó, Dorina Gabriella ; Csóka, Ildikó</creatorcontrib><description>The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and process parameters (PPs) (settings of the preparation method). The identification of the quality target product profile for a liposome-based formulation, the critical quality attributes of the liposomes, and the possible MAs and PPs that may influence the key characteristics of the vesicles facilitates pharmaceutical research. Researchers can systematise their knowledge by using the quality by design (QbD) approach. The potential factors that influence the quality of the product can be collected and studied through a risk assessment process. In this paper, the requirements of a liposome formulation prepared via the thin-film hydration preparation technique are presented; furthermore, the possible factors that have an impact on the quality of the final product and have to be considered and specified during the development of a liposomal formulation are herein identified and collected. The understanding and the application of these elements of QbD in the pharmaceutical developments help to influence the quality, the achievements, and the success of the formulated product.</description><identifier>ISSN: 1999-4923</identifier><identifier>EISSN: 1999-4923</identifier><identifier>DOI: 10.3390/pharmaceutics12121164</identifier><identifier>PMID: 33260443</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>critical factors ; Design of experiments ; Drug dosages ; Generations ; liposome formulation ; Nanoparticles ; Pharmaceutical industry ; Polyethylene glycol ; quality by design ; quality planning ; Risk assessment ; Software ; thin-film hydration method</subject><ispartof>Pharmaceutics, 2020-11, Vol.12 (12), p.1164</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3</citedby><cites>FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3</cites><orcidid>0000-0003-3953-9831</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2467238502/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2467238502?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,36994,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33260443$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Németh, Zsófia</creatorcontrib><creatorcontrib>Pallagi, Edina</creatorcontrib><creatorcontrib>Dobó, Dorina Gabriella</creatorcontrib><creatorcontrib>Csóka, Ildikó</creatorcontrib><title>A Proposed Methodology for a Risk Assessment-Based Liposome Development Process</title><title>Pharmaceutics</title><addtitle>Pharmaceutics</addtitle><description>The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and process parameters (PPs) (settings of the preparation method). The identification of the quality target product profile for a liposome-based formulation, the critical quality attributes of the liposomes, and the possible MAs and PPs that may influence the key characteristics of the vesicles facilitates pharmaceutical research. Researchers can systematise their knowledge by using the quality by design (QbD) approach. The potential factors that influence the quality of the product can be collected and studied through a risk assessment process. In this paper, the requirements of a liposome formulation prepared via the thin-film hydration preparation technique are presented; furthermore, the possible factors that have an impact on the quality of the final product and have to be considered and specified during the development of a liposomal formulation are herein identified and collected. The understanding and the application of these elements of QbD in the pharmaceutical developments help to influence the quality, the achievements, and the success of the formulated product.</description><subject>critical factors</subject><subject>Design of experiments</subject><subject>Drug dosages</subject><subject>Generations</subject><subject>liposome formulation</subject><subject>Nanoparticles</subject><subject>Pharmaceutical industry</subject><subject>Polyethylene glycol</subject><subject>quality by design</subject><subject>quality planning</subject><subject>Risk assessment</subject><subject>Software</subject><subject>thin-film hydration method</subject><issn>1999-4923</issn><issn>1999-4923</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1P3DAQhi3UqiDKTyiK1Esvaf3t-FJp-WqRFoFQe7YcZ7ybbbJO7QSJf4_DUgSo9sEjzzOv_I4HoU8Ef2VM42_D2sbeOpjG1iVC8yaS76EDorUuuabs3Yt4Hx2ltMF5MUYqpj-gfcaoxJyzA3S9KG5iGEKCpriCcR2a0IXVfeFDLGxx26Y_xSIlSKmH7Vie2JlbtpkPPRRncAddGObUrOIy9hG997ZLcPR0HqLfF-e_Tn-Wy-sfl6eLZekEFmMpGLOEaC69rLgSjaot195VUtcgndOEskroJhvztXAgFYbsklLJMHeicuwQXe50m2A3Zohtb-O9CbY1jxchroyNuTsdGOVJUynBtKeSywa0q7GXoLzSzipQWev7TmuY6h4al-1E270SfZ3ZtmuzCndGKYkrxbPAlyeBGP5OkEbTt8lB19kthCkZyqWkmjM6o5_foJswxW1u1Uyp2TammRI7ysWQUgT__BiCzTwB5r8TkOuOXzp5rvr33-wBJlmvrg</recordid><startdate>20201129</startdate><enddate>20201129</enddate><creator>Németh, Zsófia</creator><creator>Pallagi, Edina</creator><creator>Dobó, Dorina Gabriella</creator><creator>Csóka, Ildikó</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3953-9831</orcidid></search><sort><creationdate>20201129</creationdate><title>A Proposed Methodology for a Risk Assessment-Based Liposome Development Process</title><author>Németh, Zsófia ; Pallagi, Edina ; Dobó, Dorina Gabriella ; Csóka, Ildikó</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>critical factors</topic><topic>Design of experiments</topic><topic>Drug dosages</topic><topic>Generations</topic><topic>liposome formulation</topic><topic>Nanoparticles</topic><topic>Pharmaceutical industry</topic><topic>Polyethylene glycol</topic><topic>quality by design</topic><topic>quality planning</topic><topic>Risk assessment</topic><topic>Software</topic><topic>thin-film hydration method</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Németh, Zsófia</creatorcontrib><creatorcontrib>Pallagi, Edina</creatorcontrib><creatorcontrib>Dobó, Dorina Gabriella</creatorcontrib><creatorcontrib>Csóka, Ildikó</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Németh, Zsófia</au><au>Pallagi, Edina</au><au>Dobó, Dorina Gabriella</au><au>Csóka, Ildikó</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Proposed Methodology for a Risk Assessment-Based Liposome Development Process</atitle><jtitle>Pharmaceutics</jtitle><addtitle>Pharmaceutics</addtitle><date>2020-11-29</date><risdate>2020</risdate><volume>12</volume><issue>12</issue><spage>1164</spage><pages>1164-</pages><issn>1999-4923</issn><eissn>1999-4923</eissn><abstract>The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and process parameters (PPs) (settings of the preparation method). The identification of the quality target product profile for a liposome-based formulation, the critical quality attributes of the liposomes, and the possible MAs and PPs that may influence the key characteristics of the vesicles facilitates pharmaceutical research. Researchers can systematise their knowledge by using the quality by design (QbD) approach. The potential factors that influence the quality of the product can be collected and studied through a risk assessment process. In this paper, the requirements of a liposome formulation prepared via the thin-film hydration preparation technique are presented; furthermore, the possible factors that have an impact on the quality of the final product and have to be considered and specified during the development of a liposomal formulation are herein identified and collected. The understanding and the application of these elements of QbD in the pharmaceutical developments help to influence the quality, the achievements, and the success of the formulated product.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>33260443</pmid><doi>10.3390/pharmaceutics12121164</doi><orcidid>https://orcid.org/0000-0003-3953-9831</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1999-4923
ispartof Pharmaceutics, 2020-11, Vol.12 (12), p.1164
issn 1999-4923
1999-4923
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7f1d87539f2646de9cb0f6e7f79ca7e7
source Publicly Available Content Database; PubMed Central
subjects critical factors
Design of experiments
Drug dosages
Generations
liposome formulation
Nanoparticles
Pharmaceutical industry
Polyethylene glycol
quality by design
quality planning
Risk assessment
Software
thin-film hydration method
title A Proposed Methodology for a Risk Assessment-Based Liposome Development Process
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T16%3A36%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Proposed%20Methodology%20for%20a%20Risk%20Assessment-Based%20Liposome%20Development%20Process&rft.jtitle=Pharmaceutics&rft.au=N%C3%A9meth,%20Zs%C3%B3fia&rft.date=2020-11-29&rft.volume=12&rft.issue=12&rft.spage=1164&rft.pages=1164-&rft.issn=1999-4923&rft.eissn=1999-4923&rft_id=info:doi/10.3390/pharmaceutics12121164&rft_dat=%3Cproquest_doaj_%3E2467238502%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c505t-533a11946f68475d7ba49fc869be6cc9123859d121fb5ce670e212226304c58c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2467238502&rft_id=info:pmid/33260443&rfr_iscdi=true